MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

This study has 2 cohorts: MOZART-ES cohort (for extensive-stage SCLC) and MOZART-LS cohort (for limited-stage SCLC). MOZART-ES cohort: Study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizumab every 3 weeks for 4 cycles. After 4 cycles, subjects will continue maintenance treatment with durvalumab plus monalizumab every 4 weeks until disease progression, unacceptable toxicity, decision to stop study treatment, or withdrawal of consent. Patients who have received one prior cycle of treatment before enroll

Trial Details

NCT ID
NCT05903092
Phase
PHASE2
Sponsor
Hirva Mamdani
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • Durvalumab
  • Monalizumab
  • Carboplatin or Cisplatin
  • Etoposide
Locations (sample)
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Charlottesville, Virginia, United States|38.02931,-78.47668

Key Eligibility Criteria

  • Written informed consent and HIPAA authorization for release of personal health information prior to registration. Note: HIPAA authorization may be…
  • Age ≥ 18 years at the time of consent.
  • Demonstrate adequate organ function. All screening labs to be obtained within 28 days prior to registration.
  • Absolute Neutrophil Count (ANC) \> 1500mm\^3

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →